TiNivo-2 Study Shows Comparable Patient-Reported Outcomes in RCC

Kathryn Beckermann, MD, PhD, assistant professor in the Department of Medicine, Division of Hematology and Oncology at Vanderbilt School of Medicine in Nashville, Tennessee, discusses how the patient-reported outcomes for tivozanib (Fotivda) plus nivolumab (Opdivo) from the phase 3 TiNivo-2 study (NCT04987203) compare with tivozanib monotherapy in terms of quality of life for the treatment of patients with locally advanced or metastatic clear cell renal cell carcinoma (RCC) following progression on 1 or 2 systemic therapies, including at least 1 immune checkpoint inhibitor.

Data on patient-reported outcomes were presented at the 2025 Genitourinary Cancers Symposium. Findings presented at the meeting showed that tivozanib maintained the mean scores for the Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index-Disease-Related Symptoms (FKSI-DRS) and European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires.

She then delves into explaining what the key takeaways for integrating these therapies into clinical practice are for patients with RCC who have previously received an immune checkpoint inhibitor.

Transcription:

0:10 | So, I think for our community oncologists, we now have 2 great trials: CONTACT-03 [NCT04338269] and now TiNivo-2, that both say continuation of [immunotherapy] treatment in the refractory setting has no benefit. I think what this trial additionally showed was that there was no increased toxicity across the arms, which was great to see, and [that] further gave us confidence for the use of tivozanib in patients with refractory kidney cancer now and even you know earlier lines of treatment.

REFERENCE

1. Beckermann K, Choueiri T, Motzer R, et al. Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): results of the phase 3 TiNivo-2 study. J Clin Oncol. 2025;43(suppl 5):459. doi:10.1200/JCO.2025.43.5_suppl.459